Resultados globales: 1 registros encontrados en 0.02 segundos.
Artículos, Encontrados 1 registros
Artículos Encontrados 1 registros  
1.
16 p, 3.4 MB CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors / Dragon, Anna Christina (Hannover Medical School) ; Beermann, Luca Marie (Hannover Medical School) ; Umland, Melina (Hannover Medical School) ; Bonifacius, Agnes (Hannover Medical School) ; Malinconico, Chiara (Hannover Medical School) ; Ruhl, Louisa (Hannover Medical School) ; Kehler, Patrik (Glycotope GmbH) ; Gellert, Johanna (Glycotope GmbH) ; Weiß, Lisa (Glycotope GmbH) ; Mayer-Hain, Sarah (Glycotope GmbH) ; Zimmermann, Katharina (Hannover Medical School) ; Riese, Sebastian (Hannover Medical School) ; Thol, F. (Department of Hematology. Hannover Medical School) ; Beutel, Gernot (Hannover Medical School) ; Maecker-Kolhoff, B. (Department of Pediatric Hematology and Oncology. Hannover Medical School) ; Yamamoto, Felicitas (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Blasczyk, Rainer (Hannover Medical School) ; Schambach, Axel (Hannover Medical School) ; Hust, Michael (Department of Medical Biotechnology. Technical University of Braunschweig) ; Hudecek, Michael (Department of Internal Medicine II. University Hospital of Würzburg) ; Eiz-Vesper, Britta (Hannover Medical School) ; Universitat Autònoma de Barcelona
Introduction: Chimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high expression on the tumor but no expression on healthy cells, since "on-target/off-tumor" cytotoxicity is usually intolerable. [...]
2023 - 10.3389/fimmu.2023.1219165
Frontiers in immunology, Vol. 14 (2023) , p. 1219165  

Vea también: autores con nombres similares
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.